The journey of Ms Kiran Mazumdar-Shaw — the challenges she faced as a woman entrepreneur, and how she built Biocon India into a multi-billion-dollar biotechnology company that puts affordable medicine first.
A KEVOS® summary of her talk on entrepreneurship
Introduction
In this talk, Ms Kiran Mazumdar-Shaw looks back on how Biocon India came to be. Her story is organised around two questions every founder eventually faces.
What challenges did she face as a woman entrepreneur? Capital, credibility and convention — everything worked against her at the start.
How did she become a successful entrepreneur? A research-led company, a mission built on affordability, and a business model that beat the multinationals.
Professional Journey
Biocon India is established. An accidental beginning that would reshape Indian biotechnology.
Listed on the Bombay Stock Exchange — Biocon India becomes a billion-dollar company.
Valued at more than US $5 billion, with a workforce of 12,000 people.
Ms Mazumdar-Shaw still holds more than 60% of Biocon India — she built the company and kept it.
The Starting Line
Nothing about Biocon’s beginning was easy. In 1978, almost every door a founder needs to walk through was closed to her.
She wasn’t planning to be a founder at all — she was searching for a job. She became an entrepreneur accidentally, when an Irish businessman asked her to be his business partner in the company he wanted to start in India.
At that time it was not easy to bring Foreign Direct Investment into India, making an international partnership even harder to fund.
She did not have enough money of her own to start the business — and outside money proved just as difficult to raise.
During recruitment, people were reluctant to join Biocon India. Many could not accept a woman as their boss and felt the job would not be secure.
No collateral. She had nothing to pledge against a loan.
A high-risk, unknown industry. Biotechnology was a new concept — bankers had no knowledge of it and saw only risk.
A first without precedent. She was the first woman starting a business of this kind — and lenders had never backed one before.
Philosophy of Biocon India
Biocon India should be driven by research first — science is the engine of the company, not a department within it.
The company should be a place where scientists can build careers and do meaningful work in India.
Biocon India employs 12,000 people — and half of them are scientists.
Mission of Biocon India
“To produce medicines that can be bought by 100 crore people.”
One hundred crore — a billion people. Affordability isn’t a side effect of the business; it is the business.
Strategy
Multinational pharmaceutical companies and Biocon India sell medicine — but they run on opposite business models.
“Low Volume, High Value”
“High Volume, Low Value”
Impact
The model isn’t theory — it shows up directly in the price of life-saving medicine.
Diabetes medicine typically costs ₹50–100 per day, and insulin cost about $5 per day. After years of work to bring that down, Biocon India announced at a United Nations forum that its insulin will cost 10 cents a day — about ₹7.
Trastuzumab once cost ₹2 lakh per dose — ₹20–50 lakh over a year of treatment. Biocon India set out to build a biosimilar Trastuzumab for the world: it launched at ₹50,000, and today costs less than ₹20,000 per dose — while access to the medicine has expanded more than ten-fold.
Biocon has also developed Biomab, a medicine for head-and-neck cancer.
| Medicine | Earlier cost | Biocon price today | Change |
|---|---|---|---|
| Insulin (diabetes) | 10¢ (≈ ₹7) per day | −98% | |
| Trastuzumab biosimilar (breast cancer) | under ₹20,000 per dose | −90% |
More than ten times the access. Cutting the price didn’t just save patients money — it multiplied the number of people who could be treated at all.
Key Learnings
Five lessons from the Biocon story, in the order every entrepreneur meets them.
Opportunity can arrive unannounced — Biocon began with an unexpected partnership offer. Recognise it when it comes.
No experience, no capital, no bank support — every barrier has a way around it if you keep determining one.
A clear mission — medicine for 100 crore people — guided every decision Biocon made.
High volume at low margins beat low volume at high margins — and served far more people.
Continuous investment in R&D is what makes a better-quality product possible at a lower price.